Matthew Ros
2019
In 2019, Matthew Ros earned a total compensation of $2.1M as Chief Strategy and Business Officer at Epizyme, a 21% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $199,861 |
|---|---|
| Option Awards | $899,137 |
| Salary | $432,600 |
| Stock Awards | $538,793 |
| Other | $11,598 |
| Total | $2,081,989 |
Ros received $899.1K in option awards, accounting for 43% of the total pay in 2019.
Ros also received $199.9K in non-equity incentive plan, $432.6K in salary, $538.8K in stock awards and $11.6K in other compensation.
Rankings
In 2019, Matthew Ros' compensation ranked 5,724th out of 13,971 executives tracked by ExecPay. In other words, Ros earned more than 59.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,724 out of 13,971 | 59th |
Division Manufacturing | 2,143 out of 5,701 | 62nd |
Major group Chemicals And Allied Products | 772 out of 2,200 | 65th |
Industry group Drugs | 649 out of 1,886 | 66th |
Industry Pharmaceutical Preparations | 476 out of 1,398 | 66th |
Pay ratio
| Matthew Ros' Pay | $2,081,989 |
|---|---|
| Median Employee's Pay | $302,723 |
| Pay Ratio | 7to 1 |
In 2019, the annual total compensation of Matthew Ros was $2,081,989.
The annual total compensation of the median employee at Epizyme was $302,723.
The ratio of Matthew Ros' pay to the pay of median employee was therefore 7 to one.
Source: SEC filing on April 17, 2020.
Ros' colleagues
We found four more compensation records of executives who worked with Matthew Ros at Epizyme in 2019.